FDA Brief

Warning letters Drugs

FDA warning letter to

Supergoop!

MediumIssued Aug 6, 2025Posted Aug 12, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Supergoop! that its over-the-counter sunscreen body mousse is illegally labeled because foam dosage forms are not allowed under the sunscreen monograph.

What happened

FDA reviewed the product labeling, website, and Instagram/Facebook pages on May 2, 2025, and found the body mousse offered for sale without a prescription. The labeling says "Broad Spectrum Sunscreen SPF 50" and "Helps prevent sunburn," making it an over-the-counter (OTC) sunscreen drug. FDA says no approved application covers it and no final order allows sunscreen in foam/mousse dosage form, so the product is misbranded (does not meet the drug marketing requirements).

What FDA found

  1. Labeling claims such as "Broad Spectrum Sunscreen SPF 50" and "Helps prevent sunburn" make the body mousse a drug intended for OTC sunscreen use.

    FD&C Act section 201(g)(1)(B)/(C), 21 U.S.C. 321(g)(1)(B)/(C)
  2. The product is marketed without an FDA-approved drug application.

    FD&C Act section 505, 21 U.S.C. 355
  3. Sunscreen in foam, mousse, or whip dosage form may not be marketed without an approved application unless FDA issues an order allowing it; no such final order exists.

    FD&C Act section 505G(m)(2), 21 U.S.C. 355h(m)(2)
  4. Because it does not comply with section 505G and has no approved application, the nonprescription drug is misbranded.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  5. Shipping a misbranded drug in interstate commerce violates the law.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA asks Supergoop! to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If the company disagrees or cannot finish in that time, it must explain why and give a completion timeline.

Who should pay attention

  • sunscreen brands using mousse, foam, or whip dosage forms
  • retailers and online marketplaces selling OTC sunscreens
  • contract manufacturers and labs supporting OTC sunscreen monograph claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  2. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk
  3. Persōn & Covey, Inc.

    FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.

    High risk
  4. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk